Study #2024-1162
A Phase 1b/2 Study Of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against CD19 And B-Cell Maturation Antigen (BCMA) In Participants With Relapsed/Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Mahmoud Gaballa
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.